secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0001213900-23-023667
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Israeli Ministry of Health approves Raphael Pharma's Phase IIa COVID-19 trial for cannabis-based drug
--------------------------------------------------------------------------------

- Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.
- The trial protocol was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022.
- The trial involves a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/0001213900-23-023667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/ea175896-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-023667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer